Abstract
Brain metastases occur in 15-20% of patients with cancer and are generally associated with an overall poor prognosis. Currently, radiotherapy and surgery are the mainstay of palliative therapy for patients with brain metastases, while the role of systemic chemotherapy remains uncertain. In this article, we report complete responses to irinotecan-based chemotherapy in three patients with brain metastases from parotid adenocarcinoma, esophageal adenocarcinoma and small cell lung cancer. Irinotecan-based chemotherapy may hold promise in treating patients with brain metastases. Further studies are warranted to confirm our observations.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 242-245 |
| Number of pages | 4 |
| Journal | Journal of Clinical Neuroscience |
| Volume | 12 |
| Issue number | 3 |
| DOIs | |
| State | Published - Apr 2005 |
Fingerprint
Keywords
- Brain metastases
- Irinotecan
- Whole brain radiation
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health
- Neurology
Cite this
Complete response of brain metastases to irinotecan-based chemotherapy. / Chou, Rachel; Chen, Allan; Lau, Derick H.
In: Journal of Clinical Neuroscience, Vol. 12, No. 3, 04.2005, p. 242-245.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Complete response of brain metastases to irinotecan-based chemotherapy
AU - Chou, Rachel
AU - Chen, Allan
AU - Lau, Derick H
PY - 2005/4
Y1 - 2005/4
N2 - Brain metastases occur in 15-20% of patients with cancer and are generally associated with an overall poor prognosis. Currently, radiotherapy and surgery are the mainstay of palliative therapy for patients with brain metastases, while the role of systemic chemotherapy remains uncertain. In this article, we report complete responses to irinotecan-based chemotherapy in three patients with brain metastases from parotid adenocarcinoma, esophageal adenocarcinoma and small cell lung cancer. Irinotecan-based chemotherapy may hold promise in treating patients with brain metastases. Further studies are warranted to confirm our observations.
AB - Brain metastases occur in 15-20% of patients with cancer and are generally associated with an overall poor prognosis. Currently, radiotherapy and surgery are the mainstay of palliative therapy for patients with brain metastases, while the role of systemic chemotherapy remains uncertain. In this article, we report complete responses to irinotecan-based chemotherapy in three patients with brain metastases from parotid adenocarcinoma, esophageal adenocarcinoma and small cell lung cancer. Irinotecan-based chemotherapy may hold promise in treating patients with brain metastases. Further studies are warranted to confirm our observations.
KW - Brain metastases
KW - Irinotecan
KW - Whole brain radiation
UR - http://www.scopus.com/inward/record.url?scp=17844383213&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17844383213&partnerID=8YFLogxK
U2 - 10.1016/j.jocn.2004.08.007
DO - 10.1016/j.jocn.2004.08.007
M3 - Article
C2 - 15851073
AN - SCOPUS:17844383213
VL - 12
SP - 242
EP - 245
JO - Journal of Clinical Neuroscience
JF - Journal of Clinical Neuroscience
SN - 0967-5868
IS - 3
ER -